A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
A Phase 1, Double-blind (Investigator and Participant), First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CVL-354 in Healthy Participants
Sponsor: Cerevel Therapeutics, LLC
A PHASE1 clinical study on Healthy Participants, this trial is completed. The trial is conducted by Cerevel Therapeutics, LLC and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Jan 2022 — Jan 2023 [monthly]
Recruiting PHASE1
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cerevel Therapeutics, LLC
- National Institute on Drug Abuse (NIDA)
For direct contact, visit the study record on ClinicalTrials.gov .